1305 completed, 490 recruiting, 389 unknown, 359 terminated. 1882 Phase 2, 773 Phase 1, 720 Phase 3, 57 Not applicable, 35 Phase 4.
Follow Carboplatin: new trials by email Literature Review of Carboplatin trials Research Report on Carboplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 16 | 2027-06-01 | 2026-02-05 |
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer AST-201, Paclitaxel, Carboplatin - Advanced Ovarian Cancer | Phase 2 | Not yet recruiting | Aston Sci. Inc. | 98 | 2027-06-01 | 2026-10-27 |
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC Zotatifin, carboplatin - Phase IB, Zotatifin | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-02-12 | 2026-09-08 |
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer | Phase 3 | Not yet recruiting | Asan Medical Center | 172 | 2026-12-31 | 2026-10-29 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-04 | 2026-10-30 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
Showing 20 of 3134. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (813) · Lung Neoplasms (349) · Ovarian Neoplasms (331) · Breast Neoplasms (280) · Fallopian Tube Neoplasms (160) · Small Cell Lung Carcinoma (152) · Triple Negative Breast Neoplasms (151) · Neoplasms (140) · Squamous Cell Carcinoma of Head and Neck (129) · Carcinoma, Ovarian Epithelial (115) · Neoplasm Metastasis (91) · Head and Neck Neoplasms (82) · Endometrial Neoplasms (81) · Esophageal Neoplasms (74) · Uterine Cervical Neoplasms (74)
National Cancer Institute (NCI) (141) · M.D. Anderson Cancer Center (75) · Merck Sharp & Dohme LLC (74) · AstraZeneca (68) · Eli Lilly and Company (59) · Hoffmann-La Roche (57) · Bristol-Myers Squibb (47) · Memorial Sloan Kettering Cancer Center (43) · Alliance for Clinical Trials in Oncology (42) · Children's Oncology Group (42) · SCRI Development Innovations, LLC (37) · Sun Yat-sen University (30) · AbbVie (28) · Fudan University (24) · Pfizer (23)
United States (1707) · China (733) · Spain (423) · France (376) · Canada (344) · Italy (339) · Germany (320) · United Kingdom (308) · South Korea (300) · Australia (286) · Japan (246) · Belgium (224) · Poland (222) · Taiwan (208) · Netherlands (204)
PMID 37185961, PMID 37465924, PMID 21941283, PMID 32450725, PMID 35511917, PMID 37419867, PMID 38431043, PMID 38642841, PMID 39113428, PMID 21502559, PMID 29658856, PMID 33084020, PMID 33358660, PMID 35170751, PMID 36184621, PMID 36795388, PMID 37407274, PMID 40932107, PMID 40966692, PMID 10655437, PMID 16239238, PMID 16394300, PMID 18398152, PMID 19692680, PMID 19901100, PMID 20567002, PMID 22204724, PMID 22204725, PMID 22248721, PMID 22547591, PMID 23683550, PMID 23831416, PMID 23860537, PMID 24794243, PMID 25057165, PMID 25092775, PMID 25403584, PMID 26254683, PMID 27465021, PMID 27718847, PMID 27745820, PMID 28434660, PMID 29658848, PMID 30002437, PMID 30280635, PMID 31395089, PMID 31545689, PMID 32101663, PMID 32305010, PMID 33231285
2023 (77), U10CA180868 (45), 2016 (37), 2018 (35), 2025 (32), 2017 (29), 2014 (28), 2015 (25), U10CA027469 (25), U10CA180820 (22), 2019 (21), U10CA031946 (21), U10CA180886 (21), U10CA032102 (18), U10CA098543 (18)